ArticleBiomarkers in medicine2025
Serum asprosin, ox-LDL, and LOX-1 levels in patients with hypertension and their association with cardiovascular risk.
Article in Biomarkers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Asprosin as a Potential Link Between Vascular Inflammation and Disease Activity in Behçet's Disease.Journal of clinical laboratory analysis · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimOur study aimed to investigate the relationship between oxidized low-density lipoprotein(ox-LDL), lectin-like ox-LDL receptor-1 (LOX-1), inducible nitric oxide synthase(iNOS), endothelin 1(ET-1), and asprosin levels with cardiovascular risk.
methodThe study is a case-control study. 177 patients (87 HT/90 controls) were included in the study. Biochemical parameters and blood pressure were measured. Cardiovascular risk was calculated using the European Society of Cardiology Cardiovascular Diseases (ESC CVD) risk calculator. Asprosin, oxLDL, LOX1R, ET1 and iNOS levels were measured using Enzyme-Linked ImmunoSorbent Assay (ELISA) kits in blood samples obtained after a minimum 8-hour fasting period. In statistical analyses,
resultsAge was significantly higher in the patient group than in the control group(
conclusionET1 and ox-LDL were lower in the HT group treated with antihypertensive therapy compared to the control group. Moreover, asprosin was found to be low in patients with high cardiovascular risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.